Although cellular immunotherapy can achieve good outcomes, only a small proportion of cancer patients are being treated via this approach, with extremely long waitlists. Furthermore, applying centralized manufacturing workflows to individualized products results in complex logistics, creating laborious and non-standardized processes that elevate drug costs.
In this upcoming webinar on Thursday, October 26, 10:00-11:00 AM ET (4:00 PM CET), Patrick Schmidt, PhD, Senior Research Associate at the German Cancer Research Center (DKFZ) will explore how to streamline CAR-T cell product manufacturing processes for immunotherapy. The presentation will highlight how combining rapid large-scale transfection technology with single cell-based selection can shorten CAR-T product manufacturing times.